Dr. Joe Gray, Ph.D., is now Professor Emeritus at OHSU. This is his former lab page.
Joe W. Gray has licensed technologies to Abbott Diagnostics and Danaher, and has ownership positions in PDX Pharmaceuticals and Convergent Genomics.
Dr. Gray also serves as an advisor to New Leaf Ventures and KromaTiD.
Dr. Gray currently receives funding from Thermo Fisher Scientific (formerly FEI), Dahaner (Cepheid), Micron, PDX Pharmaceuticals, Susan G. Komen Foundation, the NCI Cancer Systems Biology Consortium, the NCI Human Tumor Atlas Network, the NIH LINCS program, the Radiation Effects Research Foundation (RERF), and the Brenden-Colson Center for Pancreatic Care.